Clinical Trial Update: A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BL-M07D1 to investigator's choice chemotherapy in HER2-low recurrent/metastatic breast cancer is currently recruiting. Sponsor: Sichua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-M07D1

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HER2-low Breast Cancer | Phase 3 | Status: RECRUITING